FDA Approves Boston Scientific's (BSX) Blazer OI Catheter
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the Blazer Open-Irrigated (OI) radiofrequency ablation catheter. The Blazer OI catheter has been approved to treat Type I atrial flutter, an abnormal rhythm of the upper chambers of the heart. The approval of the Blazer OI catheter marks the first time Boston Scientific will offer an open-irrigated catheter to the U.S. market.
The Blazer OI catheter is designed for use in ablation procedures to restore a normal heart rhythm for patients in atrial flutter. During the procedure, localized electrical energy is delivered through an electrode on the tip of a catheter into the heart muscle, creating heat to destroy a small area of the tissue responsible for the abnormal heart rhythm. The newly-approved Blazer OI catheter features Total Tip Cooling™ technology intended to cool the catheter tip consistently during the ablation procedure, improving the quality of the ablation lesion.
The Blazer OI catheter was granted approval based on data from the BLOCk-CTI clinical trial, a prospective, randomized trial that enrolled 302 patients at 24 sites in the U.S. and evaluated the safety and effectiveness of the Blazer OI catheter in patients with sustained or recurrent Type 1 atrial flutter.
"Successful results from the BLOCk-CTI trial demonstrate that the Blazer open-irrigated catheter is safe and effective for the ablation of atrial flutter," said Tom McElderry, M.D., principal investigator, associate professor and section chief of electrophysiology at the University of Alabama at Birmingham. "This newly approved ablation tool was built on the proven Blazer platform of therapeutic catheters and facilitates excellent maneuverability, consistent cooling and stability during procedures."
In January, the company also received CE Mark for the IntellaTip MiFi™ open-irrigated (OI) catheter for use in all cardiac ablation procedures. The IntellaTip MiFi OI catheter is designed to provide physicians precise, multidimensional information via mini-electrodes which deliver a highly localized signal reflecting exactly what is happening at the tip of the catheter in real-time during the ablation procedure. The IntellaTip MiFi OI catheter also features the same Total Tip Cooling technology as the Blazer OI catheter.
"These approvals attest to our continued focus and expansion in the electrophysiology space," said Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management. "The Blazer and IntellaTip MiFi open-irrigated catheters provide electrophysiologists with technology that leverages our established platforms to help improve the health of patients around the world."
In the U.S., the IntellaTip Mifi OI catheter is an investigational device and is not available for sale.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Scientific (BSX) Elects David S. Wichmann To Board Of Directors
- Turtle Beach (HEAR) Sings NBA Player Immanuel Quickley as Gaming Partner
- Incyte (INCY) Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!